IMNM logo

IMNM
Immunome Inc

2,236
Mkt Cap
$2.64B
Volume
638,956.00
52W High
$27.65
52W Low
$7.15
PE Ratio
-9.52
IMNM Fundamentals
Price
$23.11
Prev Close
$23.33
Open
$23.49
50D MA
$21.96
Beta
1.51
Avg. Volume
976,741.54
EPS (Annual)
-$2.43
P/B
4.12
Rev/Employee
$39,214.69
$1,226.67
Loading...
Loading...
News
all
press releases
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +15.55% and -0.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8h ago
News Placeholder
More News
News Placeholder
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the...
Business Wire·9h ago
News Placeholder
Truist Financial Upgrades Immunome (NASDAQ:IMNM) to Strong-Buy
Truist Financial upgraded shares of Immunome to a "strong-buy" rating in a report on Monday...
MarketBeat·18h ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
Immunome (IMNM) to Release Earnings on Monday
Immunome (NASDAQ:IMNM) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-immunome-inc-stock...
MarketBeat·2d ago
News Placeholder
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application...
Business Wire·7d ago
News Placeholder
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Immunome, Inc. (Immunome) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its...
Business Wire·15d ago
News Placeholder
JPMorgan Chase & Co. Cuts Stock Holdings in Immunome, Inc. $IMNM
JPMorgan Chase & Co. decreased its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 94.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,603 shares of the company's stock after selling 5...
MarketBeat·21d ago
News Placeholder
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the firm, Marketbeat Ratings...
MarketBeat·21d ago
News Placeholder
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
Key Points9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026...
Nasdaq News: Markets·1mo ago
<
1
2
...
>

Latest IMNM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.